Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy.

× No keyword cloud information.

10 in total

1. Stochastic models of receptor oligomerization by bivalent ligand.

Authors: Tomás Alarcón; Karen M Page
Journal: J R Soc Interface Date: 2006-08-22 Impact factor: 4.118

2. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

Authors: M A Ghetie; E M Podar; A Ilgen; B E Gordon; J W Uhr; E S Vitetta
Journal: Proc Natl Acad Sci U S A Date: 1997-07-08 Impact factor: 11.205

3. Tumor dormancy and cell signaling: anti-mu-induced apoptosis in human B-lymphoma cells is not caused by an APO-1-APO-1 ligand interaction.

Authors: E Racila; R Hsueh; R Marches; T F Tucker; P H Krammer; R H Scheuermann; J W Uhr
Journal: Proc Natl Acad Sci U S A Date: 1996-03-05 Impact factor: 11.205

Review 4. Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Authors: Daniel T Nagasawa; Christina Fong; Andrew Yew; Marko Spasic; Heather M Garcia; Carol A Kruse; Isaac Yang
Journal: Neurosurg Clin N Am Date: 2012-07 Impact factor: 2.509

5. Connections between signal transduction components and cellular responses initiated by antigen receptor on B lymphocytes.

Authors: R H Scheuermann; J W Uhr
Journal: J Exp Med Date: 1995-10-01 Impact factor: 14.307

Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy.

1. Stochastic models of receptor oligomerization by bivalent ligand.

2. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

3. Tumor dormancy and cell signaling: anti-mu-induced apoptosis in human B-lymphoma cells is not caused by an APO-1-APO-1 ligand interaction.

Review 4. Passive immunotherapeutic strategies for the treatment of malignant gliomas.

5. Connections between signal transduction components and cellular responses initiated by antigen receptor on B lymphocytes.

Review 6. Rituximab: mechanisms and applications.

7. Rational design of CXCR4 specific antibodies with elongated CDRs.

8. Efficient release of immunocaptured cells using coiled-coils in a microfluidic device.

Review 9. Production of monoclonal antibodies in plants for cancer immunotherapy.

10. Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody.